CLINICAL_TRIALS
trial_result
· 2013-08-09
Clinical Trial Update: Campath in Chronic GVHD [Phase 1]
Summary
A Phase 1 study of Campath (alemtuzumab) for chronic graft-versus-host disease; results were posted in 2013.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Chronic Graft-vs.-Host Disease | Phase 1 | Status: COMPLETED | Results posted: 2013-08-09